Chronic kidney disease remains a significant challenge for patients with diabetic nephropathy, especially those progressing to end-stage renal disease. Managing microinflammation in peritoneal dialysis has emerged as a critical factor for improving patient longevity and treatment quality. While peritoneal dialysis offers a flexible treatment option, persistent systemic inflammation often compromises its effectiveness. Recently, researchers developed a predictive model to identify high-risk patients by analyzing specific immune markers and their impact on dialysis efficacy.

In a prospective cohort study involving 236 patients, researchers categorized participants into high-inflammation and microinflammation groups. They utilized serum levels of C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) to define these categories. Consequently, the study tracked essential clinical data, such as infection rates, survival outcomes, and dialysis efficiency measured by Kt/V. These biochemical indicators provided a clear window into the physiological stress experienced by patients undergoing long-term dialysis.

Impact of Microinflammation in Peritoneal Dialysis Efficacy

The results indicated that the high-inflammation group experienced significantly lower dialysis efficiency compared to those with lower inflammatory markers. Specifically, lower Kt/V values in these patients pointed toward a reduced ability to clear uremic toxins. Furthermore, patients with elevated inflammation markers faced higher infection rates and decreased overall survival. Therefore, identifying these inflammatory patterns early is vital for modifying treatment plans and improving patient prognosis. The predictive model built via logistic regression successfully identified key predictors of poor outcomes, offering clinicians a practical tool for risk stratification.

Addressing these inflammatory markers allows for more personalized care in diabetic nephropathy. For instance, early intervention with anti-inflammatory strategies or adjustments in the dialysis prescription may mitigate the adverse effects of chronic systemic stress. Clinicians should monitor immune markers regularly to ensure the dialysis remains effective and to prevent secondary complications associated with persistent microinflammation.

Frequently Asked Questions

Which markers are most useful for predicting dialysis outcomes?

According to the latest research, serum levels of CRP, IL-6, and TNF-α are robust indicators of microinflammation. These markers correlate strongly with reduced dialysis efficiency and higher mortality rates in patients with diabetic nephropathy.

How does microinflammation affect dialysis efficiency?

Chronic inflammation can lead to changes in the peritoneal membrane and systemic vascular dysfunction. This reduces the clearance of waste products (measured by Kt/V), thereby decreasing the overall effectiveness of the peritoneal dialysis treatment.

Can early prediction models improve patient survival?

Yes. By using early prediction models, healthcare providers can identify high-risk individuals sooner. This allows for timely medical interventions, such as adjusting dialysis protocols or managing underlying inflammatory drivers, which can lead to better survival outcomes.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.

References

Zhou M et al. Impact of immune marker-based microinflammation on dialysis efficacy in diabetic nephropathy patients: Development of an early prediction model. Clin Nephrol. 2026 Mar 07. doi: 10.5414/CN111843. PMID: 41793703.

Stenvinkel P et al. Inflammation in end-stage renal disease: the role of cytokines. J Nephrol. 2025.

Yeun JY et al. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2024.